Fragonomics: fragment-based drug discovery.
The use of smaller molecules (fragments) in the drug discovery process has led to success in delivering novel leads for many different targets. This process is a highly integrated process, starting from library design to screening and medicinal chemistry. An overview of this process is presented with particular emphasis placed on the NMR aspect of screening.
Zartler
Edward R
ER
Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285, USA. zartler_edward@lilly.com
Shapiro
Michael J
MJ
D018360:Crystallography, X-Ray; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D004364:Pharmaceutical Preparations / Q000737:chemistry*
D004364:Pharmaceutical Preparations